Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Eric brings extensive experience in dairy nutrition, animal health and territory development, having worked closely with ...

The Last Check on PC. This guide breaks down movement, inspection tools, interface keys, base commands, and how to customize ...

Developer Embark Studios releases a new ARC Raiders update for January 2026, as patch 1.11.0 brings some big balance ...

ExxonMobil Chemical, in collaboration with Milliken & Company and materials recycler Ravago, has published a new case study ...

A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...